9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY)

NCT06896188 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG: Retifanlimab
DRUG: Chemotherapy
DRUG: 9-ING-41

Sponsor

Anwaar Saeed

Collaborators

[object Object]
[object Object]